Thus, we have demonstrated that the well-described role played by the KP in mediating cancer immune tolerance extends beyond IDO1, potentially identifying KMO and KYNU inhibitors as new therapeutic BrCa targets. Here, KMO is linked to invasive breast carcinoma.